Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review

Reh, Christina Southern; Geffner, Mitchell E.

doi:10.2147/cpaa.s6525

Cited by 22 publications

(12 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Growth hormone (GH) therapy has become the standard of care for girls with TS and should be considered as soon as decreased linear growth velocity is apparent (4,9). Several studies have shown that GH therapy accelerates growth velocity and improves final adult stature.…”

Section: Growth Hormone In Tsmentioning

confidence: 99%

The patient with Turner syndrome: puberty and medical management concerns

González¹,

Witchel²

2012

Fertility and Sterility

View full text Add to dashboard Cite

Turner Syndrome (TS) affects approximately 1 in 2500 liveborn females and is characterized by loss or structural anomalies of an X chromosome. Clinical features vary among patients; multiple organ systems can be affected. Endocrinologists are involved in the management of short stature, delayed puberty, and infertility. Endocrine therapies can include growth hormone, estrogen, and progestagen to promote linear growth and pubertal development. The duration of estrogen and progestagen treatment (HRT) is generally more than 40 years. There is not one standard HRT protocol that is suitable for all women. Thus, general guidelines are provided for HRT to induce pubertal development. Additional considerations regarding choice of HRT include thrombotic risk and disorders associated with thrombophila. Involvement of cardiologists is important because approximately 50% of patients with TS have congenital structural cardiac anomalies linked to an increased risk for aortic dissection and rupture. Although oocyte donation offers the chance to carry a pregnancy, accumulating information has highlighted the potential dangers associated with pregnancy. Advances in the care of infants, girls, and women with TS have been achieved. Management of infants, girls, and women with TS involves coordinated care from a multi-disciplinary team including endocrinologists, cardiologists, geneticists, otolaryngologists, behavioral health experts, nurse educators, and social workers.

show abstract

Section: Growth Hormone In Tsmentioning

confidence: 99%

The patient with Turner syndrome: puberty and medical management concerns

González¹,

Witchel²

2012

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“… 6 – 9 Recombinant human growth hormone (rhGH) treatment still remains the only established active treatment option to effectively correct growth failure and increase stature. 10 The primary objective of the treatment during childhood and adolescence is to accelerate and normalize height velocity and linear growth, returning the child to the normal growth curve, in order to attain a “normal” or near-normal final adult height within the genetic mid-parental height potential. 7 , 11 – 13 RhGH treatment is administered via a daily subcutaneous injection, given by the parent/caregiver or self-administered within the home environment.…”

Section: Introductionmentioning

confidence: 99%

<p>Exploring Potentially Modifiable Factors That Influence Treatment Non-Adherence Amongst Pediatric Growth Hormone Deficiency: A Qualitative Study</p>

Graham

Auyeung

Weinman

2020

PPA

View full text Add to dashboard Cite

Introduction: A recent systematic review found that up to 71% of children with growth hormone deficiency and their families are non-adherent to treatment as prescribed. A key way to better understanding the complex issue of pediatric non-adherence is to explore the perceptions and experiences of the parent/caregiver. Our study is the first to look specifically at the potentially modifiable factors that influence non-adherence to rhGH treatment amongst parents/caregivers of children with this endocrine disorder. Methods: Fourteen semi-structured telephone interviews were conducted to explore parents/ caregivers' perceptions and experiences of their child's condition and prescribed treatment, in addition to their perceived relationship with their healthcare professional. The findings were thematically analyzed and narratively synthesized, in line with the qualitative approach of Braun and Clarke (2006). Results: Potentially modifiable factors that influence non-adherence to growth hormone treatment were grouped under four themes: 1. Device Burdens, 2. Treatment Considerations, 3. Logistical Interferences and 4. Interpersonal Influences. Conclusion: Our exploratory study presents the wide range of potentially modifiable factors that influence the way in which growth hormone treatment is used. These findings can, in turn, be used to inform and promote the development of targeted, adherence-focused interventions, to support growth hormone deficient children and their families and optimize the use of prescribed growth hormone treatment within endocrine clinical practice.

show abstract

“…This gland is responsible for the secretion of somatotropin, the main effect of which is the stimulation of growth during childhood and the maintenance of a healthy body by increasing the volume of muscles and the consumption of fat mass. Additionally, somatotropin is responsible for keeping the concentration of glucose in blood stable [ 12 ].…”

Section: Fda -Approved and -Withdrawn Drugsmentioning

confidence: 99%

Targeting Energy Expenditure—Drugs for Obesity Treatment

et al. 2021

View full text Add to dashboard Cite

Obesity and overweight are associated with lethal diseases. In this context, obese and overweight individuals infected by COVID-19 are at greater risk of dying. Obesity is treated by three main pharmaceutical approaches, namely suppressing appetite, reducing energy intake by impairing absorption, and increasing energy expenditure. Most compounds used for the latter were first envisaged for other medical uses. However, several candidates are now being developed explicitly for targeting obesity by increasing energy expenditure. This review analyzes the compounds that show anti-obesity activity exerted through the energy expenditure pathway. They are classified on the basis of their development status: FDA-approved, Withdrawn, Clinical Trials, and Under Development. The chemical nature, target, mechanisms of action, and description of the current stage of development are described for each one.

show abstract

Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review

Cited by 22 publications

References 77 publications

The patient with Turner syndrome: puberty and medical management concerns

The patient with Turner syndrome: puberty and medical management concerns

<p>Exploring Potentially Modifiable Factors That Influence Treatment Non-Adherence Amongst Pediatric Growth Hormone Deficiency: A Qualitative Study</p>

Targeting Energy Expenditure—Drugs for Obesity Treatment

Contact Info

Product

Resources

About